Stockscreener 앱 받기
2.44
14.39%
0.32
Vor Biopharma Inc 주식(VOR)의 최신 뉴스
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer - Yahoo Finance
Vor Biopharma Faces Crucial Market Shifts Amid Latest Developments - StocksToTrade
Vor Biopharma Stock Faces Volatile Week Amid Mixed Financial Reports - timothysykes.com
How Vor Biopharma Inc. stock performs during market volatilitySafe Entry High Exit Alerts - Newser
What makes Vor Biopharma Inc. stock price move sharplySmart Money Signals - Newser
Why Vor Biopharma Inc. stock attracts strong analyst attentionBreakout Confirmation Tool - Newser
Vor Biopharma Stock’s Rollercoaster: Time to Buy? - StocksToTrade
VOR’s 2025 Market Dance: Up 174.66% – Time to Invest? - investchronicle.com
Vor Biopharma Explodes 22% – What’s Fueling the Surge? - AInvest
Vor Biopharma Names Sandy Mahatme as CFO, Chief Business Officer - MarketScreener
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer - The Manila Times
Vor Bio Strengthens Leadership: Top Biotech Executive Who Raised $6B Joins as New CFO/CBO - Stock Titan
Vor Biopharma Sees Unusually High Options Volume (NYSE:VOR) - Defense World
Vor Biopharma Shares Soar 23.22% on Analyst Upgrades - AInvest
Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants - Seeking Alpha
VOR’s Unexpected Surge: What’s Driving the Spike? - timothysykes.com
VOR Biopharma Inc. Faces Uncertain Future Amid Recent Developments - StocksToTrade
Vor Biopharma Soars 19.1% on Analyst Upgrade - AInvest
Vor Biopharma Stock Skyrockets: What’s Next? - StocksToTrade
Vor Biopharma shares surge 28.01% intraday after licensing telitacicept for autoimmune diseases and raising $1.75B in private funding. - AInvest
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Vor Biopharma (NASDAQ:VOR) Stock Rating Upgraded by HC Wainwright - Defense World
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Massive CEO Stock Grant: Vor Bio Awards 83M Shares to New Chief Executive at $0.89 - Stock Titan
Vor Biopharma (NYSE:VOR) Rating Increased to Buy at HC Wainwright - Defense World
Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market - Benzinga
Vor Biopharma (VOR) Receives Upgrade to Buy Rating by HC Wainwri - GuruFocus
Vor Biopharma stock rating upgraded to Buy by H.C. Wainwright on telitacicept deal - Investing.com
Vor Biopharma (VOR) Receives Upgrade to Buy Rating by HC Wainwright & Co. | VOR Stock News - GuruFocus
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why - Yahoo Finance
VOR SEC FilingsVor Biopharma Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Mysterious Surge at Vor Biopharma: A Deep-Dive Analysis - AInvest
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy - MSN
After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept - BioWorld MedTech
Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact - insights.citeline.com
PureTech's Vor Bio Lands $4B Autoimmune Drug Deal, Names New CEO, Raises $175M - Stock Titan
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset - Yahoo Finance
Vor Biopharma Stock Rises 1.72% Amid Mixed Analyst Forecasts - AInvest
Short Interest in Vor Biopharma Inc. (NYSE:VOR) Increases By 51.8% - Defense World
Vor Biopharma Inc (VOR) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Market Insights: Triller Group Inc (ILLR)’s Notable Gain of 1.91, Closing at 0.69 - DWinneX
Vor Biopharma Inc (VOR) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Data-Based Insights About Vor Biopharma Inc (VOR) - Stocksregister
Vor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of “Hold” by Analysts - Defense World
Northern Trust Corp Acquires 44,252 Shares of Vor Biopharma Inc. (NYSE:VOR) - Defense World
Cambridge biotech company researching blood cancers to close, lay off 155 - Yahoo Finance
Vor Biopharma Inc (NASDAQ: VOR) Stock Forecast: Could Pass $6 In A Year - Stocksregister
Vor Biopharma draws downgrades on strategic review - MSN
Vor Biopharma’s SWOT analysis: biotech firm halts programs, explores options By Investing.com - Investing.com South Africa
Vor Biopharma’s SWOT analysis: biotech firm halts programs, explores options - Investing.com
Vor Biopharma Approves Share Increase at Annual Meeting - TipRanks
Vor Biopharma Appoints Robert Ang as CFO - TipRanks
What Did We Note About Insider Trading At Vor Biopharma Inc (NASDAQ: VOR)? - Stocksregister
FMR LLC's Strategic Acquisition of Vor Biopharma Inc Shares - GuruFocus
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Hold” by Analysts - Defense World
Vor Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vor Biopharma Inc. SEC 10-Q Report - TradingView
3.69%
2.49%
자본화:
|
볼륨(24시간):